1.Study on effectiveness of different concentration of ropivacaine on elderly patients with brachial plexus block under ultrasound-guided
Yishan LIU ; Jianlong DU ; Xiuhong HUANG
Chongqing Medicine 2016;(1):53-55
Objective To observe and compare the effect of different concentration of ropivacaine on elderly patient with bra-chial plexus block under ultrasound-guided ,to assess its effectiveness and security ,so as to determine the optimum dosage of anes-thetic for elderly patients with brachial plexus block .Methods 120 patients undergoing elective surgery of forearm or hand in this hospital from February 2013 to December 2014 were selected as the observation group in this study .These patients were randomly divided into four groups on average ,narcosis was conducted in each group with ultrasound-guided :group A with 30 mL of 0 .250%ropivacaine ,group B with 30 mL of 0 .375% ropivacaine ,group C with 30 mL of 0 .500% ropivacaine ,group D with 30 mL of 0 .750% ropivacaine .The onset time of sensory block ,motor block level ,duration of analgesia and adverse reactions were observed and recorded .Results With the increase of concentration of ropivacaine ,the onset time of narcotize became shorter(P< 0 .05) and duration of analgesia became longer(P < 0 .05) .There were no significant difference in the effects of brachial plexus block (P>0 .05) .There was no complications occurred in four groups after narcosis .Conclusion Concentration of ropivacaine more than 0 .375% can achieve perfect clinical effect on elderly patients with brachial plexus block under guidance of ultrasound .
2.Glucosamine hydrochloride tablets alone and combination with Xianlinggubao capsules for treatment patients with knee osteoarthritis
Yishan LIU ; Jianlong DU ; Xiuhong HUANG
Chinese Journal of Primary Medicine and Pharmacy 2015;(20):3044-3047
Objective To explore the clinical value of Glucosamine hydrochloride tablets(GH)alone and combination with Xianlinggubao capsules(XLGB)for treatment patients with knee osteoarthritis(KOA).Methods 96 patients with KOA were selected,and were divided into two groups according to the random number method, 48 cases in each group.The control group was treated with GH alone,while the observation group was treated with XL-GB on the basis of the control group.US Western Ontario and McMaster University Osteoarthritis Index (WOMAC) were used to evaluate the symptoms change,including pain,stiffness,physical function scores and total scores before and after treatment.The onset time,knee function (HSS)score at 3 months and 6 months after treatment were recor-ded.CRP and ESR were measured,and the total efficacy was evaluated at the end of treatment.Results The differ-ence of WOMAC score between the two groups was not statistically significant before treatment (P >0.05 ).After treatment,pain,stiffness,physical function scores and total scores were (10.2 ±1.4)points,(3.5 ±1.6)points, (40.5 ±5.0)points and (56.4 ±6.7)points in the observation group,those were (14.8 ±2.6)points,(6.2 ±2.3)points, (52.2 ±6.8)points and (73.3 ±4.5)points in the control group,the differences were statistically significant (t =7.631,4.721,6.791,10.26,all P <0.01).The onset time,HSS score at 3 months and 6 months after treatment in the observation group were (6.0 ±2.2)d,(68.2 ±6.4)points and (84.3 ±6.2)points,while those were (9.8 ± 2.8)d,(58.5 ±3.9)points and (72.8 ±5.4)points in the control group,the differences were statistically significant (t =5.228,6.341,6.852,all P <0.01 ).The improvements of CRP level and ESR in the observation group were more pronounced than those in the control group (t =3.880,2.668,all P <0.05).After treatment,the total effective rate of the observation group was 93.8%(45 /48),while that was 77.1%(37 /48)in the control group,the difference was statistically significant (χ2 =5.352,P <0.05).Conclusion GH combines with XLGB can significantly improve symptoms in patients with KOA,with more rapid recovery of knee function,thus it is a safe and effective therapy.
3.CT 、MRI and~1H-MRS Diagnosis of Central Neurocytoma:A Report of 7 Cases with Literature Review
Bin ZHAO ; Hongjuan PENG ; Yishan DU ; Shifeng CAI
Journal of Practical Radiology 2001;0(07):-
Objective To discuss CT,MR and~1H-MRS features of central neurocytoma(CNC).Methods Imaging findings ofneurocytomas in 7 cases confirmed by pathology were retrospectively analyzed with literature review.2 cases were examined by CT、MR and~1 H-MRS,2 cases only by MR,and 3 cases only by CT.Results All the tumors were located in the lateral ventricles.There were different degree hydrocephalus in all cases.The masses were heterogeneous appearance on CT with necrotic area and fine to course calcifications.Heterogeneous enhancement was seen in the solid portion.The tumors were isointense and hypointense on T_1WI and heterogeneous on T_2WI.Heterogeneous enhancement was also seen on MRI.The in vivo~1H-MRS showed prominent choline(Cho) and low N-acetyl aspartate(NAA) compared to the normal.Conclusion Central neurocytoma should be considered when a tumor was located at the lateral ventricles especially septum pellucidum in young patients.CT,MR and~1H-MRS are helpful in making a preoperative diagnosis.
4.Optimization of the Formulation of Roxatidine Acetate Hydrochloride Sustained-release Tablets by Central Composite Design-response Surface Methodology
Yishan DUAN ; Juan DU ; Lu SUN ; Xueyi LI ; Ning LIN
China Pharmacy 2018;29(7):927-929
OBJECTIVE:To optimize the formulation of Roxatidine acetate hydrochloride(ROX)sustained-release tablets. METHODS:ROX sustained-release tablets were prepared by direct powder compression method. Central composite design-response surface methodology was used to optimize the formulation with composite index of 1,4,8 h in vitro accumulative release rate as index,using mass ratio of lactose/microcrystalline cellulose(MCC)(m/m),ethyl cellulose(EC)amount and HPMC amount as factors. Validation test was also conducted. RESULTS:The optimal formulation was as follows as ROX 75 mg,lactose 45 mg, MCC 91 mg,EC 65 mg,HPMC 124 mg,micropowder silica gel 2 mg. 1,4,8 h in vitro accumulative release rates of prepared sustained-release tablets were(30.7 ± 0.5)%,(65.8 ± 0.7)%,(89.4 ± 0.6)%,respectively. Related errors of them to predicted value were 0.6%,0.8%,1.2%,respectively. CONCLUSIONS:ROX sustained-release tablets are prepared successfully,and sustained-release effect is consisted with the expected effect.
5. Research progress of the therapy in comorbidity of bipolar disorder and alcohol use disorder
Hong GUO ; Xiangyu CHANG ; Yishan DU ; Yan XIA
Chinese Journal of Behavioral Medicine and Brain Science 2019;28(10):947-950
Mood disorders and substance use disorders often co-occur, but few evidence-based data have been conducted to guide the management of comorbidity bipolar disorder with alcohol use disorder.Therefore, it's lack of clinical researches and expert consensus.This review inducted the research progress of the comorbidities of bipolar disorder and alcohol use disorder in recent years, and finds that drug treatment or combined treatment with other treatment methods has certain curative effect suggesting that the comprehensive treatment of drug or combined non-drug treatment for comorbidities is the future direction.
6.Research progress of the therapy in comorbidity of bipolar disorder and alcohol use disorder
Hong GUO ; Xiangyu CHANG ; Yishan DU ; Yan XIA
Chinese Journal of Behavioral Medicine and Brain Science 2019;28(10):947-950
Mood disorders and substance use disorders often co-occur,but few evidence-based data have been conducted to guide the management of comorbidity bipolar disorder with alcohol use disorder. Therefore,it's lack of clinical researches and expert consensus. This review inducted the research progress of the comorbidities of bipolar disorder and alcohol use disorder in recent years,and finds that drug treatment or combined treatment with other treatment methods has certain curative effect suggesting that the comprehen-sive treatment of drug or combined non-drug treatment for comorbidities is the future direction.
7.Clinical characteristics of severe acute respiratory syndrome coronavirus 2 vaccine breakthrough infections in children
Fu WEI ; Jian WANG ; Xiaofeng LI ; Xinyuan HE ; Yishan LIU ; Xiaoqin HU ; Huan DENG ; Ying WANG ; Ning GAO ; Hong DU ; Sirui MA ; Fanpu JI
Chinese Journal of Infectious Diseases 2023;41(1):58-63
Objective:To analyze the clinical characteristics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine breakthrough infections in children, and to provide reference basis for the SARS-CoV-2 vaccination in children.Methods:A total of 97 children aged 3 to 14 years and diagnosed with coronavirus disease 2019 (COVID-19) admitted to Xi′an People′s Hospital (Xi′an Fourth Hospital) from December 27, 2021 to February 7, 2022 were included. According to the COVID-19 vaccination status, the enrolled children were divided into unvaccinated group, partially vaccinated group and fully vaccinated group, and the clinical data of the children in the three groups were collected and compared. Chi-square test, two independent sample t-test and Kruskal-Wallis H test were used for statistical analysis. Results:Totally 97 children including 49 males and 48 females were enrolled, with 87(89.7%) children of mild type, 10(10.3%) children of common type, and no severe or critical case. The proportions of unvaccinated, partially vaccinated and fully vaccinated preschool-aged children (3 to 6 years old) were 56.5%(13/23), 30.8%(12/39) and 17.1%(6/35), respectively, while those of school-aged children (7 to 14 years old) were 43.5%(10/23), 69.2%(27/39) and 82.9%(29/35), respectively. The vaccination proportion in preschool-aged children was significantly lower than that in school-age children ( χ2=9.94, P=0.007). The proportion of the children with fever in fully vaccinated group was 17.1%(6/35), which was lower than that in unvaccinated group (43.5%, 10/23), and the difference was statistically significant ( χ2=4.82, P=0.028). The cycle threshold (Ct) values of the open reading frame ( ORF)1 ab gene in the unvaccinated, partially vaccinated and fully vaccinated groups were 33.77(26.87, 36.58), 35.23 (33.45, 38.57) and 37.12 (34.91, 39.39), respectively, and there was a statistically significant difference among the groups ( H=7.76, P=0.021). The Ct values of the nucleocapsid protein ( N) gene in the three groups were 32.26(25.85, 36.18), 35.12(33.18, 37.96) and 37.26(34.27, 39.24), respectively, and the difference among the groups was statistically significant ( H=7.84, P=0.020). The Ct values of ORF1 ab gene and N gene in fully vaccinated group were higher than those in unvaccinated group, and the differences were statistically significant ( Z=-2.69, P=0.007 and Z=-2.39, P=0.017, respectively). The duration of viral shedding in fully vaccinated children was (9.9±4.1) d, which was shorter than that in unvaccinated children ((12.8±3.7) d), and the difference was statistically significant ( t=2.72, P=0.009). Conclusions:The majority of children with breakthrough infections with SARS-CoV-2 are mild. Vaccination may effectively shorten the duration of viral shedding. And fully vaccination is associated with mild clinical symptoms and lower serum viral load compared to unvaccinated children.
8.Psilocybin facilitates fear extinction in mice by promoting hippocampal neuroplasticity.
Yingjie DU ; Yunfeng LI ; Xiangting ZHAO ; Yishan YAO ; Bin WANG ; Liming ZHANG ; Guyan WANG
Chinese Medical Journal 2023;136(24):2983-2992
BACKGROUND:
Posttraumatic stress disorder (PTSD) and depression are highly comorbid. Psilocybin exerts substantial therapeutic effects on depression by promoting neuroplasticity. Fear extinction is a key process in the mechanism of first-line exposure-based therapies for PTSD. We hypothesized that psilocybin would facilitate fear extinction by promoting hippocampal neuroplasticity.
METHODS:
First, we assessed the effects of psilocybin on percentage of freezing time in an auditory cued fear conditioning (FC) and fear extinction paradigm in mice. Psilocybin was administered 30 min before extinction training. Fear extinction testing was performed on the first day; fear extinction retrieval and fear renewal were tested on the sixth and seventh days, respectively. Furthermore, we verified the effect of psilocybin on hippocampal neuroplasticity using Golgi staining for the dendritic complexity and spine density, Western blotting for the protein levels of brain derived neurotrophic factor (BDNF) and mechanistic target of rapamycin (mTOR), and immunofluorescence staining for the numbers of doublecortin (DCX)- and bromodeoxyuridine (BrdU)-positive cells.
RESULTS:
A single dose of psilocybin (2.5 mg/kg, i.p.) reduced the increase in the percentage of freezing time induced by FC at 24 h, 6th day and 7th day after administration. In terms of structural neuroplasticity, psilocybin rescued the decrease in hippocampal dendritic complexity and spine density induced by FC; in terms of neuroplasticity related proteins, psilocybin rescued the decrease in the protein levels of hippocampal BDNF and mTOR induced by FC; in terms of neurogenesis, psilocybin rescued the decrease in the numbers of DCX- and BrdU-positive cells in the hippocampal dentate gyrus induced by FC.
CONCLUSIONS
A single dose of psilocybin facilitated rapid and sustained fear extinction; this effect might be partially mediated by the promotion of hippocampal neuroplasticity. This study indicates that psilocybin may be a useful adjunct to exposure-based therapies for PTSD and other mental disorders characterized by failure of fear extinction.
Humans
;
Mice
;
Animals
;
Psilocybin/metabolism*
;
Fear
;
Extinction, Psychological
;
Brain-Derived Neurotrophic Factor/metabolism*
;
Bromodeoxyuridine/pharmacology*
;
Hippocampus/metabolism*
;
Neuronal Plasticity
;
TOR Serine-Threonine Kinases/metabolism*